3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Terminated
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Sarcoma
3
Lung Neoplasms
3
Head and Neck Neoplasms
3
Breast Neoplasms
3
Brain Neoplasms
3
Stomach Neoplasms
2
Pancreatic Neoplasms
2
Neuroectodermal Tumors
2
Nervous System Diseases
2
Neoplasms, Neuroepithelial
2
Neoplasms, Nerve Tissue
2
Neoplasms
2
Liver Neoplasms
2
Gliosarcoma
2
Glioma
2
Glioblastoma
2
Colorectal Neoplasms
2
Carcinoma
2
Virus Diseases
1
Urinary Bladder Neoplasms
1
Small Cell Lung Carcinoma
1
Pharyngeal Neoplasms
1
Ovarian Neoplasms
1
Otorhinolaryngologic Neoplasms
1
Nose Neoplasms
1
Neoplasms, Glandular and Epithelial
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms by Histologic Type
1
Melanoma
1
Laryngeal Neoplasms
1
Interventions
human papillomavirus vaccine, L1 type 16, 18
3
valrubicin
1
ledipasvir, sofosbuvir drug combination
1
hepatitis C immune globulin, human
1
halofantrine
1
VP-102
1
Therapies, Investigational
1
Papillomavirus Vaccines
1
Oncolytic Virotherapy
1
Mitomycin
1
Ipilimumab
1
Interferons
1
Influenza Vaccines
1
Immunoglobulin G
1
Imiquimod
1
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
1
Gemcitabine
1
Gels
1
Drug Therapy
1
Cantharidin
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Virus Diseases
×
Oncolytic Virotherapy
×
Clear all
NCT01438112
2021-04-14
BOND
CG Oncology, Inc.
Phase 2/3
Terminated
22 enrolled